军事知识服务平台
从"最大耐受干预"到"最小有效治疗":上海肺癌外科40年的学科沿革与时代变革
From"maximum tolerated intervention"to"minimum effective treatment":four decades of evolution and transformation in lung cancer surgery in Shanghai
摘要 上海市抗癌协会成立40年来,肺癌外科经历了从经验驱动到循证医学指导、从最大范围切除到个体化保肺、从单纯追求肿瘤切除到兼顾患者长期生存和生活质量的深刻变革.40年前,肺癌多以晚期、中央型、吸烟相关疾病形态进入临床视野,外科治疗侧重于开胸肺叶切除、全肺切除和系统性淋巴结清扫.随着低剂量计算机断层扫描(low-dose computed tomography,LDCT)筛查、高分辨率影像、世界卫生组织(World Health Organization,WHO)2015版肺腺癌新分类系统、术中快速冷冻切片病理学检查、微创技术及多学科诊疗的发展,早期肺癌尤其是磨玻璃结节(ground-glass opacity,GGO)型肺癌逐渐成为胸外科临床的重要对象.以上海为代表的中国肺癌外科实践,较早面对非吸烟女性肺癌、低龄、低频筛查、肺小结节和GGO管理等筛查时代新问题,并围绕外科治愈窗口期、微创手术3.0、亚肺叶切除、选择性淋巴结处理和多发GGO主动监测形成了具有特色的研究体系.2016年J Clin Oncol发表的术中快速冷冻切片病理学检查研究,将肺腺癌病理学新分类从术后报告前移到术中决策,为小肺腺癌个体化切除提供了重要依据;日本临床肿瘤协作组(Japan Clinical Oncology Group,JCOG)、美国癌症与白血病协作组B(Cancer and Leukemia Group B,CALGB)及亚洲东部胸部肿瘤协作组(Eastern Cooperative Thoracic Oncology Projects,ECTOP)系列研究进一步推动早期肺癌外科从"习惯性扩大"走向"证据性克制".本文围绕过去40年肺癌外科理念、疾病谱和证据体系的变化,重点讨论GGO型肺癌的自然病程、治疗不足与过度治疗的边界、外科治愈窗口期的提出及其对未来精准管理的意义.面向未来,肺癌外科仍需围绕治愈窗口期、影像-病理-分子融合、人工智能辅助风险判断和长期生活质量评价继续深化,使治疗从"尽可能充分"进一步走向"恰到好处".
Abstract:
Over the past four decades since the establishment of the Shanghai Anti-Cancer Association,lung cancer surgery has undergone a profound transformation from experience-based practice to evidence-guided decision-making,from maximal resection to individualized parenchymal preservation,and from a sole focus on tumor removal to a broader concern for long-term survival and quality of life.Four decades ago,lung cancer mostly presented as advanced,centrally located,smoking-related disease,and surgical treatment relied mainly on thoracotomy with lobectomy or pneumonectomy and systematic lymph node dissection.With the development of low-dose computed tomography screening,high-resolution imaging,the 2015 World Health Organization(WHO)classification of lung adenocarcinoma,intraoperative frozen section pathology,minimally invasive techniques,and multidisciplinary care,early-stage lung cancer,particularly ground-glass opacity(GGO)-type lung cancer,has gradually become a major focus of thoracic surgical practice.Chinese lung cancer surgical practice,represented by Shanghai,has addressed emerging issues of the screening era at an early stage,including lung cancer in nonsmoking women,screening strategies with a younger starting age and lower frequency,and the management of pulmonary nodules and GGOs,and has developed a distinctive research system centered on the surgical curative time window,minimally invasive surgery 3.0,sublobar resection,selective lymph node management,and active surveillance of multifocal GGOs.The intraoperative frozen section study published in J Clin Oncol in 2016 moved the new pathological classification of lung adenocarcinoma from postoperative reporting to intraoperative decision-making,providing important evidence for individualized resection strategies for small lung adenocarcinomas;the series of studies from the Japan Clinical Oncology Group(JCOG),the Cancer and Leukemia Group B(CALGB),and the Eastern Cooperative Thoracic Oncology Projects(ECTOP)have further driven early lung cancer surgery from"habitual extension"toward"evidence-based restraint".This article reviews the changes in surgical concepts,disease spectrum,and evidence system of lung cancer surgery over the past 40 years,focusing on the natural history of GGO-type lung cancer,the boundary between undertreatment and overtreatment,and the proposal of the surgical curative time window and its significance for future precision management.In the future,lung cancer surgery should continue to advance along the curative time window,the integration of imaging,pathology,and molecular information,artificial intelligence-assisted risk assessment,and long-term quality-of-life evaluation,so that treatment can move from"as sufficient as possible"toward"precisely appropriate".
刊 名 中国癌症杂志 ISTICPKU
年,卷(期): 2026, 36(9)
分类号: R734.2
机标分类号: R730 F127.5 R318
在线出版日期: 2026年11月2日